Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
Biogen (BIIB) Receives a Buy From Truist Financial
Argus Raises Biogen's Price Target to $250 From $240
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)
Blueprint Medicines Analyst Ratings
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Piper Sandler Keeps Their Buy Rating on Exact Sciences (EXAS)
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Exact Sciences Analyst Ratings
Analysts' Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)
Buy Rating Affirmed for Exact Sciences on Strong Performance and Promising Growth Initiatives
Buy Rating Affirmed for Exact Sciences Amidst Strong Growth and Innovative Pipeline
Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating
Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)
Blueprint Medicines Analyst Ratings
Blueprint Medicines Analyst Ratings
JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125
Biogen Analyst Ratings
HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating
Wells Fargo Remains a Buy on Blueprint Medicines (BPMC)